On 12th November 1993, Bruno C. Wassmer – a pharmaceutical specialist from Freiburg - , Gernot Harrant – a chemist from Salzburg – and Lutz Mothes – a pharmacist from Frankfurt – founded Inresa Arzneimittel GmbH after 30 years in the pharmaceutical industry and the sale of CuraMED Pharma GmbH.
In the following 4 years, dossiers were written to obtain market authorizations, scientific studies were carried out and its own research projects were developed. In 1997, Inresa’s first pharmaceutical products were approved by the BfArM (Federal Institute for Drugs and Medical Devices) in Bonn.
1997 - Entry into the market
In 1997, Inresa launched three pharmaceutical products. At that time, Henric Wassmer, the son of Bruno Wassmer, became responsible for the clinical field service in the whole of Germany and the specialized, family-run business steadily became established in the complex German hospital market.
Due to the constant growth in sales, the number of employees and marketing authorizations increased.
2003 - New premises
Soon, there was not enough space for the new employees and the multitude of stored pharmaceutical products. In 2003, the owners acquired a commercial property with a storage area for pharmaceutical products.
Today, Inresas’ pharmaceutical products are delivered from here to hospitals, to in-house pharmacies and to wholesalers as well as to public pharmacies. In adition, products are exported worldwide two or three times a day.
2006 - Generation change
After 13 years at Inresa and 40 years in the pharmaceutical industry, Bruno C. Wassmer passed on the commercial management of the Inresa Arzneimittel GmbH to his son Henric Wassmer.
However, the three founders still act as consultants and therefore their expertise remains in the company.
2010 - Entry into the international market
In 2010, Inresa ventured into international markets. This step was achieved by the partnership with Flynn Pharma Ltd. Flynn Pharma Ltd. is a fast growing pharmaceutical company located in Old Stevenage, Hertfordshire. It has operated with great success on the British and Irish pharmaceutical markets since 2004.
The group of companies – with Flynn Pharma Ltd. in the United Kingdom, Inresa Arzneimittel GmbH and Inresa GmbH & co. KG in Germany and Inresa France in France – operates in the three largest European markets and is able to serve them from a single source. Each of the companies has a similar company size, quick decision-making, good interaction and modern structures which are the driving forces behind the achievement of this goal.
2014 - Process improvement
As of April 1, 2014, Inresa Arzneimittel GmbH successfully switched to a new merchandise management system.
This enables us to sustainably optimize our work processes through fully integrated EDP-supported invoicing and warehouse automation at our headquarters in Freiburg.
Furthermore, in May 2014 the quality management of Inresa Arzneimittel GmbH was certified by TÜg GmbH according to the latest criteria of DAkkS (German Accreditation) DIN EN ISO 9001:2008.
A further decisive step on the path of continuous process optimization.
The following product launch was successfully implemented in 2014:
On July 2014, Inresa Arzneimittel GmbH launched Meropenem Inresa 500 mg and 1000 mg on the German market.
2016 - Three generations
With the apprenticeship start of Patrice Wassmer, the third generation is now part of the Inresa family. Patrice already focuses on finance during his apprenticeship as a commercial manager.
2017 - Outsourcing warehouse and dispatch
In order to increase the focus on our core competence, the logistics activity was handed over to our external logistics partner Health Logistics in the course of extensive internal restructuring.
Health Logistics is a logistics service provider specializing in the fields of pharmaceuticals, healthcare and biotechnology. Since April 1, 2017, it has been coordinating our warehousing and delivery services.
The centralization of inventories enables our company to increase storage capacity, improve delivery processes within the framework of pharmaceutical industry regulations and, above all, provide flexibility and efficiency in our core competencies.
2017 - Product lounch & ISO re-certification
The following product launch was successfully implemented:
April 2017 Terlipressin Inresa 1 mg injection solution
Furthermore, the quality management of Inresa Arzneimittel GmbH was recertified according to the latest criteria of DAkkS (German Accreditation) DIN EN ISO 9001:2015 by the Technical Inspection Association TÜg GmbH.
2017 - Our new corporate identity
After about 20 years in the business, we are pleased to present a new logo that both lives up to our tradition and conveys a contemporary, future-oriented impression. In many ways, the logo resembles our long-standing logo. The classic INRESA corporate colours were retained.
Nevertheless, a clearer, more modern form and font have been used, which is already being used for some of our materials to give the INRESA brand a uniform appearance. In addition, a new visual language was introduced to underline the design and classic lines behind the new logo.
